EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel 7-Deazapurine Incorporating Isatin Hybrid Compounds as Protein Kinase Inhibitors: Design, Synthesis, In Silico Studies, and Antiproliferative Evaluation

Mohammed M Alanazi iD, Ashwag S Alanazi iD

Molecules · 04.08.2023 · 28 (15) · 5869

DOI: 10.3390/molecules28155869 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, online erschienen am 04.08.2023. Verfasst von Mohammed M Alanazi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia. Hauptthemen laut MEDLINE: Isatin, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deputyship for Research and Innovation, "Ministry of Education" in Saudi Arabia for funding this research, Deputyship for Research and Innovation, “Ministry of Education” in Saudi Arabia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer is a multifactorial disorder with extremely complex genetics and progression. The major challenge in cancer therapy is the development of cancer resistance and relapse. Conventional anticancer drugs directly target the DNA of the cell, while modern chemotherapeutic drugs include molecular-targeted therapy, such as targeting the abnormal cell signaling inside the cancer cells. Targeted chemotherapy is effective in several malignancies; however, the success has always been limited by drug resistance and/or side effects. Anticancer with multi-targeted actions simultaneously modulates multiple cancer cell signaling pathways and, therefore, may ease the chance of effective anticancer drug development. In this research, a series of 7-deazapurine incorporating isatin hybrid compounds was designed and successfully synthesized. Among those hybrids, compound 5 demonstrated a very potent cytotoxic effect compared to the reference anticancer drug against four cancer cell lines. Likewise, compound 5 inhibited the activity of four protein kinase enzymes in nanomolar ranges. Further analysis of the biological evaluation of compound 5 revealed the capability of compound 5 to arrest cell cycle progression and induce programmed cell death. Moreover, molecular simulation studies were performed to investigate the possible types of interactions between compound 5 and the investigated protein kinases. Finally, taking into consideration all the abovementioned findings, compound 5 could be a good candidate for further investigations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IsatinAntineoplastic AgentsNeoplasmsHumansProtein Kinase InhibitorsDrug Screening Assays, AntitumorCell ProliferationStructure-Activity RelationshipMolecular StructureCell Line, TumorPurines

Stichwörter der Autor:innen

7-deazapurineanticancerisatinprotein kinase inhibitor

Substanzen

IsatinProtein Kinase InhibitorsAntineoplastic Agents7-deazapurinePurines

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.
  • Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh 11671, Saudi Arabia.

ORCID-Profile: Mohammed M Alanazi, Ashwag S Alanazi

Förderung

  • Deputyship for Research and Innovation, "Ministry of Education" in Saudi Arabia for funding this research
  • Deputyship for Research and Innovation, “Ministry of Education” in Saudi Arabia

Zitieren

APA

Alanazi, M. M., & Alanazi, A. S. (2023). Novel 7-Deazapurine Incorporating Isatin Hybrid Compounds as Protein Kinase Inhibitors: Design, Synthesis, In Silico Studies, and Antiproliferative Evaluation. Molecules, 28(15), 5869. https://doi.org/10.3390/molecules28155869

Vancouver

Alanazi MM, Alanazi AS. Novel 7-Deazapurine Incorporating Isatin Hybrid Compounds as Protein Kinase Inhibitors: Design, Synthesis, In Silico Studies, and Antiproliferative Evaluation. Molecules. 2023;28(15):5869. doi:10.3390/molecules28155869

BibTeX
@article{Alanazi2023,
  author = {Alanazi, Mohammed M and Alanazi, Ashwag S},
  title = {Novel 7-Deazapurine Incorporating Isatin Hybrid Compounds as Protein Kinase Inhibitors: Design, Synthesis, In Silico Studies, and Antiproliferative Evaluation},
  journal = {Molecules},
  year = {2023},
  volume = {28},
  number = {15},
  pages = {5869},
  doi = {10.3390/molecules28155869}
}
Kostenlos starten →